Movers: Amgen, Bristol-Myers, Carvana, Gilead, Twitter

  • Barry Adams
  • U.S.A. New York City
  • Sep 12, 2022
  • Gilead settled patent litigation with five generic drugmakers. Bristol-Myers won a regulatory approval for its oral treatment for plaque psoriasis.
Access Exclusive Global Markets Content


If you want to see the full data, please log in to your account. Logging in gives you complete access to all available information, features, and detailed insights that are not visible to guest users.